HEALTH PROFESSIONAL · SOURCE READING

Signal transduction inhibitors

Source: Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 2, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Unresectable Stage III, Stage IV, and Recurrent Melanoma / Treatment Options for Unresectable Stage III, Stage IV, and Recurrent Melanoma

Studies indicate that both BRAF and MEK inhibitors, as single agents and in combination, can significantly impact the natural history of melanoma, although they do not appear to provide a cure.

Continue within this section

BRAF inhibitors →MEK inhibitors →KIT inhibitors →Combination therapy with signal transduction inhibitors →Combination signal transduction inhibitor therapy plus PD-L1 inhibitor →

Preserved source evidence · Not medical advice